Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.
- DOI
- 10.1016/j.jpha.2026.101606
- Published
- 2026 Aug
- Container
- Journal of pharmaceutical analysis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jpha.2026.101606,
title = {Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.},
author = {Heng X and Ye C and Huang S and Zhang K and Liu Y and Wu Y and Sun N and Yang H},
year = {2026},
journal = {Journal of pharmaceutical analysis},
doi = {10.1016/j.jpha.2026.101606},
url = {https://doi.org/10.1016/j.jpha.2026.101606}
}RIS
TY - JOUR TI - Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor. AU - Heng X AU - Ye C AU - Huang S AU - Zhang K AU - Liu Y AU - Wu Y AU - Sun N AU - Yang H PY - 2026 JO - Journal of pharmaceutical analysis DO - 10.1016/j.jpha.2026.101606 UR - https://doi.org/10.1016/j.jpha.2026.101606 ER -
APA
X, H., C, Y., S, H., K, Z., Y, L., Y, W., N, S., & H, Y. (2026). Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.. Journal of pharmaceutical analysis. https://doi.org/10.1016/j.jpha.2026.101606
Source records
- pubmed · retrieved 2026-11-10T11:53:28.837Z